Retinitis Pigmentosa

Ophthalmology·MeSH: Retinitis Pigmentosa

Prevalence

25.0 / 100K

Incidence

1.5 / 100K/yr

29 drugs in development·15 companies·12 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
4D-125 IVT Injection	4D Molecular Therapeutics, Inc. (FDMT)
AAV5-hRKp.RPGR	Replimune Group, Inc. (REPL)
Control	Replimune Group, Inc. (REPL)
genetic	GH Research PLC (GHRS)
Genetic	Replimune Group, Inc. (REPL)
ocu400	Ocugen, Inc. (OCGN)
sub-retinal administration of ocu400-301	Ocugen, Inc. (OCGN)
Sub-Retinal Administration of OCU400-301	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(11)

Drug	Company
1.5 x 10^6 UC-MSC + CM	Accustem Sciences Inc. (ACUT)
100 μg kio-301	Kiora Pharmaceuticals Inc. (KPRX)
4D-125	4D Molecular Therapeutics, Inc. (FDMT)
5 x 10^6 UC-MSC + CM	Accustem Sciences Inc. (ACUT)
50 μg kio-301	Kiora Pharmaceuticals Inc. (KPRX)
ADX-2191	Aldeyra Therapeutics, Inc. (ALDX)
agtc-501	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
human retinal progenitor cells	Valneva SE (VALN)
kio-301	Kiora Pharmaceuticals Inc. (KPRX)
KPI-014	KALA BIO, Inc. (KALA)
rAAV2tYF-GRK1-hRPGRco	Replimune Group, Inc. (REPL)

Preclinical(5)

Drug	Company
ic-100	IVERIC bio, Inc. (ISEE)
nsr-cntf	Nightstar Therapeutics plc (NITE)
nsr-opn4	Nightstar Therapeutics plc (NITE)
nsr-rho	Nightstar Therapeutics plc (NITE)
rho program	Prime Medicine, Inc. (PRME)

Phase 1/Phase 2(3)

Phase 2/Phase 3(2)

Drug	Company
nsr-rpgr	Nightstar Therapeutics plc (NITE)
xlrp product candidate	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)

BioSniper tracks 29 drugs in development for Retinitis Pigmentosa across 15 companies.

There are 12 clinical trials targeting Retinitis Pigmentosa tracked by BioSniper.

The estimated prevalence of Retinitis Pigmentosa is approximately 25.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.